During cytotoxic drug therapy, CK18 is released from tumour cells and plasma levels of both full-length CK18 and ccCK18 fragments are commonly utilised to evaluate clinical progression and tumour cell death (Kramer et al. 2004). The gene discussed is KRT18; the disease is neoplasm.